

QI Collaborative Call, Adults Le hange

7/26/22

Welcome & introductions



Agenda


- Collaborative updates
 - New clinics joining the Collaborative
 - New TIDX-QI Team member
 - New measures for the 2023-2025 period
 - Annual survey
 - RSVP for the November Learning Session
 - Collaborative member website
 - August Newsletter
- July Collaborative member presentations
 - Dr. Basina, Stanford
 - Alisha Virani, RD, CDCES, Grady Memorial
- Publications updates
- Portal updates



T1D Exchange Updates



TIDX-QI network of 49 centers, caring for 72,000+ TID patients across 19 states and Washington D.C.



Priya Prahalad, Nicole Rioles et al. T1D Exchange Quality Improvement Collaborative: Accelerating Change through Benchmarking and Improvement Science for People with Type 1 Diabetes. Journal of Diabetes. November 2021



18 adult clinics – caring for 26,000+ patients with TID



49 Participating C	linics, 31 Pediatric &	a 18 Adult		
Pediatric Clinics	Lurie Children's Naomi Fogel MD	Adult Clinics Albert Einstein Shivani Agarwal MD MPH	Pediatric and Adult Clinics	
Children's Mercy Hospital Mark Clements MD PhD	Mott Children'sBillings ClinicJoyce Lee MDHaleigh James MD		Cleveland Clinic, Pratibha PR Rao MD MPH & Andrea Mucci MD MASc	
Children's Hospital Los Angeles Brian Miyazaki, MD	Nationwide Children'sBoston Medical CenterManu Kamboj MDDevin Steenkamp MD		Mount Sinai Carol Levy MD & Robert Rapaport MD	
Cincinnati Children's Hospital Sarah Corathers MD	Rady Children's, Carla Demeterco Berggren MD PhD	Grady Memorial Hospital Sonya Haw MD	NYU Langone: Lauren Golden MD & Siham Accacha MD. Hassenfeld Children's Hospital at NYU Mary Pat Gallagher MD	
CHOA Kristina Cossen MD	Seattle Children's Hospital, Faisal Malik MD, MSHS and Alissa Roberts MD	Northwestern Medicine Grazia Aleppo MD	Oregon Health & Science University Andrew Ahmann and Ines Guttmann- Bauman MD	
Cohen Children's Medical Center, Northwell Health, Jennifer Sarhis MD & Allison Mekhoubad MD	Texas Children's, Daniel DeSalvo MD	Penn Medicine Ilona Lorincz MD	Stanford University Marina Basina MD & Priya Prahalad MD	
Cook Children's Paul Thornton MD & Susan Hsieh			SUNY, Pediatrics and Adult Ruth Weinstock MD PhD Roberto Izquierdo MD	
Helen Devos Children's Donna Eng MD	University of Alabama Mary Lauren Scott MD	Wayne State University, Berhane Seyoum MD & Elizabeth Morrison MD	UCSF, Pediatrics and Adult, Umesh Masharani MD & Jenise Wong MD	
Indiana University Health Anna Neyman MD	University of Wisconsin, Madison Liz Man MD	Pediatric and Adult Clinics	University of Miami, Francesco Vendrame, MD PhD & Janine Sanchez MD	
Le Bonheur Children's, U TN Grace Bazan MD	Weill Cornell Alexis Feuer MD	Barbara Davis Center Halis Akturk MD & Todd Alonso MD	University of Pittsburgh Medical Center, Jason Ng, MD & Alissa Guarneri MD	

Washington University in St. Louis

Division of Endocrinology, Metabolism & Lipid Research

Multidisciplinary Team Members	Patient Demographics	Contact Names
 13 attending faculty 2 attending inpatient only faculty 	 ~ 8-10 newly dx T1DM patients per month 	 Site PI Alexis M.McKee, MD, CDCES
 8 fellows 3 NPs 5 CDCES 	 ~ 1500 established patients with T1DM 60% commercial insurance 	ammckee@wustl.edu Site Coordinator Becky Sidberry, NP rebeccas@wustl.edu
• 1 Foot RN	 40% Medicare/Medicaid 	

Department Division

Welcome two new University of Pittsburgh Medical Center clinics!





Adult PI: Jason Ng, MD UPMC



TIDX-QI welcomes a new team member!



Data Integration Manager Jesse Cases-Villablanca, MS, MPA



New measures for the Collaborative

- New measures will be circulated in early August
- Separate measures and definitions for Adult and Pediatric centers
- Google link will be share for a 30-day comment period
- After your feedback is collected and definitions are finalized, final measures will be distributed in October so that your analysts have 90 days to review and update/create new reports for the measures
- New measures go live Jan 1, 2023 and will remain in use until Dec 31, 2025



TIDX-QI Annual Survey

- A new survey link will be shared on Qualtrics for the TIDX-QI Annual Survey
- Survey link will be live 8/15-9/15
- Each clinic is being asked to complete 1 survey
 - Ideally you will review with your internal team members to have knowledge/consensus for your responses
 - A PDF of the survey will be shared so that you can review before answering the questions. PDF will be accessible on the T1D-QI member website
 - Topics
 - LGBTQ+
 - Equity
 - Transitions
 - Staffing





Friday 7/29 is deadline to RSVP for Learning Session

- Last day to RSVP for the November Learning Session is Friday 7/29
- Email your response to <u>Ql@tldexchange.org</u> so that we know who is attending in person or virtually/through Zoom
- Details for the event:
 - 2-day learning session: Monday November 7-Tuesday November 8
 - Activities begin by 8am on 11/7, so in person attendees are encouraged to fly in on Sunday 11/6
 - Activities end by 3pm on 11/8 so that you can fly home Tuesday evening
 - Activities will have CME/CEU credits
 - TID Exchange will cover costs for:
 - Two team member flights and hotels for two nights (We book the hotel. You book flights and we reimburse for the flights.)
 - If you wish to bring a 3rd team member, communicate that to TIDX-QI. Those expenses will need to be covered by your institution
 - Our reimbursement form/details can be found on the TID Exchange website, using this <u>link</u>




Friday 7/29 is deadline for Learning Session Abstracts

- Due COB Friday
- Abstracts should be sent to <u>Ql@tldexchange.org</u>
- Review process led by Publications Co-Chairs
- Accepted abstracts will be published in the *Journal of Diabetes*
- Accepted abstracts will be presented during the November Learning Session



TIDX-QI August Newsletter is released on Monday, 8/1





TID Exchange Website



For People with TID

For Researchers

For Clinics

For Partners Get Involved

About

News

Join / Login



We use the protected space to:

- Share work in progress, including emerging case studies and interventions
- Ask questions to the Collaborative network with the ability to view archived threads and responses




How to join website: 3 easy steps

- 1. Visit registration page: <u>https://tldx-qi.tldexchange.org/register/</u>
- 2. Register with name, title, email information. Create a password.
- **3.** TIDX-QI team gets pinged to ensure that newly registered members are affiliated with the Collaborative- and you're in!

	SPECIAL PROJECTS RE	STRICTED CONTENT	REGISTER	LOGIN	
Register					Home » Register
	First Name				
	Last Name				
	Title				
	E-mail Address				
	Display Name				



What you will find on the website



Welcome to the TIDX-QI Collaborative! We are so excited to partner with you and work together to better improve diabetes care. In this section you will be able to learn how to get engaged by joining a committee, involve your patients with advice from our parent



Clinical Presentation: Stanford




QI PROJECTS

MARINA BASINA, MD STANFORD UNIVERSITY, DIVISION OF ENDOCRINOLOGY

TROUBLE SHOOTING OF INSULIN PUMP MALFUNCTION

PUMP MALFUNCTION IS A LEADING CAUSE OF DKA AMONG INSULIN PUMP USERS



"...most of the patients [55%] had been using insulin pumps for at least 5 years, 75% knew about their settings, and 76% recognized malfunction. These data are less suggestive of a lack of expertise but instead the problem seems to rely on the lack of knowledge regarding further actions <u>after</u> recognizing a pump malfunction."

Flores M, et al. BMJ Open Diab Res Care, 2020.

Stanford Endocrine Clinic Data

Estimated total number of patients on an insulin pump using STARR cohort discovery:

At least 1,150 patients on insulin pump

Search criteria: Encounter with "Endocrine clinic" or "Hover clinic" over past 2 years, Active Rx for Aspart, Lispro, or Glulisine, Any clinical document containing keywords "Insulin pump" AND either "Omnipod," "Tandem," or "Medtronic."

Comfort level of clinic staff with guiding patients is sub-optimal

Brief survey to endocrinology clinic nurses; n = 5 responses

- All participating RNs interact with patients with DM regularly, 80% (4/5) >50% of the time
- 60% (3/5) felt not at all or only slightly confident in helping patients troubleshoot pumps over the phone
- All reported receiving multiple calls per month regarding insulin pump malfunction, median 3-5 calls per month
- Calls can take 10 to >20 min each, median 10-15 min
- Estimated percent that required contacting a physician: 26±16%
- Estimated percent ultimately not able to be handled over the phone: 31±25%

IDENTIFIED CHALLENGES AND GOALS

- Older/outdated materials
- No systematic approach, taking longer to search for issue or make plan over the phone
- Over-reliance on patients to know what to do
- Patients get frustrated on the phone
- Generic advice for patients after encounter, not targeted to specific patient

Create protocol that structures approach to patients calling with concern about insulin pump malfunction in order to:

- I. Increase confidence among nursing staff in managing pump malfunction over the phone
- 2. Limit average call time to 10 min or less
- 3. Provide patients with targeted summary/recommendations at encounter end
- 4. Better capture/track data and outcomes

DOT PHRASE: ".PUMPFAIL"

Encounter for insulin pump malfunction

- A. Initial assessment (always completed, details on next slide)
- B. Persistent hyperglycemia (Requests completion if question 3 from part A is answered, "yes." Otherwise, auto-populates, " none" here.)
- Pump troubleshooting: "Instructions type "NA" if step is not applicable. Otherwise use dotphrase,
 ".PUMPTROUBLE" to complete." ***
- D. Action plan, Summary, and Recommendations: "Instructions Use dotphrase, ".PUMPACT" to complete. Copy and paste into patient instructions for encounter" ***

A. INITIAL ASSESSMENT

I. Pump/system: (Select Tandem, Medtronic, or Omnipod) – Automated? Yes/No

2. Current glucose and recent trend

- Glucose *** mg/dl, checked at ***
- Checked by continuous glucose monitor? yes/no
 - If yes --> Select type
 - Dexcom --> Select one from associated column on table to the right
 - Medtronic --> Select one from associated column on table to the right
 - Abbot/Libre --> Select one from associated column on table to the right
 - Eversense --> Select one from associated column on table to the right
 - Other --> Current trend is ***.
 - 3. Has there been persistent hyperglycemia? Yes/No
 - Glucose >250 mg/dL >2 hours after last meal bolus
 - Glucose not corrected by ≥50 mg/dl one hour after last correction bolus

Dexcom	Medtronic	Abbot/Libre	Eversense
Rising rapidly – double up arrow (>3 mg/dl/min)	Rising rapidly – triple up arrow (>3 mg/dl/min)		
Rising – single up arrow (2-3 mg/dl/min)	Rising – double up arrow (2-3 mg/dl/min)	Rising – up arrow (>2 mg/dl/min)	Rising – up arrow (>2 mg/dl/min)
Rising slowly – oblique up arrow (1-2 mg/dl/min)	Rising slowly – single up arrow (1-2 mg/dl/min)	Rising slowly – oblique up arrow (1-2 mg/dl/min)	Rising slowly – oblique up arrow (1-2 mg/dl/min)
Steady – Horizontal arrow (<1 mg/dl/min)	Steady – Horizontal arrow (<1 mg/dl/min)	Steady – Horizontal arrow (<1 mg/dl/min)	Steady – Horizontal arrow (<1 mg/dl/min)
Falling slowly – oblique down arrow (1-2 mg/dl/min)	Falling slowly – single down arrow (1-2 mg/dl/min)	Falling slowly – oblique down arrow (1-2 mg/dl/min)	Falling slowly – oblique down arrow (1-2 mg/dl/min)
Falling – single down arrow (2-3 mg/dl/min)	Falling – double down arrow (2-3 mg/dl/min)	Falling – single down arrow (>2 mg/dl/min)	Falling – single down arrow (>2 mg/dl/min)
Falling rapidly – double down arrow >3 mg/dl/min)	Falling rapidly – triple down arrow >3 mg/dl/min)		

B. PERSISTENT HYPERGLYCEMIA: ASSESS SYMPTOMS AND KETONES

I. Symptoms and ketones assessed, as below

- Minor symptoms: Patient reports [] Thirst, [] Frequent urination, [] Nausea (uses check boxes, not drop down multi-select)
- Major symptoms: Patient reports []Vomiting, [] Blurry vision, [] Confusion, []
 Weakness, []Tiredness, [] Labored or rapid deep breathing
- Ketones were [select from single-selection drop down:"checked" OR "not checked." Result: (If "checked" --> select "Blood" and/or "Urine"; If "not checked" --> populate "NA, not checked because ***")
 - If "Blood" selected, add " *** mmol/L" to the right
 - If "Urine" selected, add " ***" to the right

2. Hyperglycemia managed per clinic algorithm

ALGORITHM, FOR REFERENCE (NOT INCLUDED IN DOT PHRASE)

Ketones	Symptoms	Ketones	Symptoms	Ketones	Symptoms
Urine: Neg-Trace Blood: <0.6 mmol/L	None	Urine: Small Blood: 0.6-1.5 mmol/L	Thirst, Frequent urination, Nausea	Urine: Mod-Large Blood: >1.5 mmol/L	Vomiting, Blurry vision, Confusion, Labored or rapid deep breathing, Severe weakness/tiredness
 Perform pump trou Exchange indicated components Use dot phrase, .PUMI Give correction do using insulin pump wi BG Document action p Use dot phrase, .PUM Monitor Drink water (1-2 glas hour) Recheck glucose in 2 Check ketones in 2 ho glucose not improving Call back clinic if no improvement or risi 	d PTROUBLE ose ith current olan 1PACT ses per hours ours (if g)	(with syringe/ Use pump cal Perform con of infusion sit reservoir, and Documenta Use dot phrat Monitor Drink water (hour) Recheck gluce glucose not in Call back cli	Action plan se, .PUMPACT (1-2 glasses per ose in 2 hours es in 2 hours (if mproving)	(with Use p 2 Cont (depe 3 Docu Use d Note bolus pump count	manual subQ injection syringe/pen) ump calculator for dose act MD or Refer to ER nding on symptom severity) ment action plan ot phrase, .PUMPACT When giving manual subQ injection, should also be programed and given via while pump is disconnected so it is ed toward "insulin on board." Advise t to do this if not already done.

C. PUMP TROUBLESHOOTING (APPEARS WITH ".PUMPTROUBLE")

I.Verify most recent bolus delivery. Give correction bolus if missed bolus is identified.

- When/how long ago was the last bolus?
- How many units was the last bolus?
- Was there any missed bolus?

2. Assess current infusion site/pod, replace if persistent hyperglycemia or if any of the below are present.

- Does the cannula appear dislodged?
- Is there ANY redness/swelling at the site?
- Is there scar tissue at the site? (Skin feels thicker, more rubbery, lumpier around site)
- Is there leaking at the site? (Inspect site for wetness (especially at/in adhesive) or smell of insulin)
- Has there been a recent "Occlusion" (Tandem/Omnipod) or "Insulin flow blocked" (Medtronic) alarm?
- Also document, approximately how old is the current infusion site?
- If removed, was the cannula kinked?

3. Assess insulin in pump reservoir/pod and replace if answers to any of the following are "yes"

- Was the pump reservoir/pod filled >3 days ago?
- Has the pump/pod been exposed to abnormally high or low temperatures (e.g. in the sun at the beach)?

4. Replace insulin in the pump using a NEW insulin vial if answers to any of the following are "yes"

- Has the vial been inconsistently refrigerated?
- Was the vial dropped or damaged?
- Has the vial expired? Expiration date _____

5. Assess tubing and connections (Medtronic & Tandem only), disconnect and "fill tubing" (Tandem) or "prime" tubing Medtronic if answers to any of the following are yes

- Are there air bubbles/visible spaces in the tubing?
- Is the reservoir or any connector loose?

**if possible, only completed entries remain in note

On our call today we, (copy & paste to patient instructions) (select from all that apply multi-select drop down)

- Discussed recommendation to go to ER
- Contacted MD
- Gave a manual subcutaneous insulin injection:*** units
- Performed targeted pump troubleshooting, which resulted in the following actions:***
- Performed a complete exchange of infusion site/pod, tubing, reservoir, and insulin
- Gave a correction dose with the insulin pump:*** units
- Reviewed that if blood sugar is not decreasing and you have moderate to high ketones, nausea, vomiting, difficulty breathing, or other worsening symptoms, you should go immediately to the EMERGENCY ROOM.

Please call back with any further questions: 650.721.1300


Call time: ***

Patient verbally confirmed completion of the above actions and acknowledged understanding of the above recommendations.

FUTURE DIRECTIONS AND INTERVENTIONS

- Implement and track usage for 6 months
- In 6 months
 - Survey nursing staff: satisfaction with protocol, confidence with pump malfunction management and troubleshooting over the phone
 - Review encounters: Number of calls, Call time, MD calls, ED visits, Hospitalizations, Number of call backs, Causes of malfunction, Inadequate supplies (e.g. ketone meter)
- If successful, create integrated patient handout based on clinic protocol to facilitate self-management and education

OTHER CURRENTLY ONGOING PROJECTS



LONG ACTING GLP-I SAFETY AND EFFICACY IN TID

PRESENTED AT ENDO SOCIETY AND ADA 2022 ANNUAL MEETINGS


EVALUATING THE EFFICACY AND SAFETY OF LONG-ACTING GLP-1 RECEPTOR AGONIST IN T1DM PATIENTS

Deene Mohandas, BA; Catherine Gao, MS; Jamie Calma, BA; Marina Basina, MD Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, California

- GLP-1 receptor agonist (RA) is a class of therapeutic agents that mimic the endogenous incretin hormone GLP-1.
 GLP-1 medications are not approved for T1DM patients due to concern of increased diabetic ketoacidosis (DKA) risk, but long-acting GLP-1 medications are commonly prescribed as adjunct therapies, off-label.
- Only one study assessing the impact of a long-acting GLP-1 in 11 T1DM patients showed no increased risk of DKA and no significant difference in time in range (Traina et al, Can J Diabetes. 2014;38(4):269-272. doi:10.1016/j.jcjd.2013.10.006)
- In our study, we aim to evaluate the safety and efficacy of long-acting GLP-1 medications in a larger cohort of T1DM patients.
- retrospective chart review using an Electronic Health Record system (EPIC)


METHODS

- Search parameters: ICD-10 code E10 for Type 1 diabetes mellitus, abnormal A1c, abnormal c-peptide, Diabetes Autoimmune Profile (includes ICA-512/IA-2 AB, GAD-65 AB and insulin AB), and celiac disease screen
- **Inclusion criteria**: adults diagnosed with T1DM, on a long-acting GLP-1 for ≥ 6 months
- **Exclusion crite**ria: pregnancy, concurrent steroid use
- 54 participants met the study criteria
- Average of 2-year data prior to initiation of GLP-1 compared with data on GLP-1
- Statistical analysis was conducted using paired t-tests on R and Excel to compare baseline and post GLP-1 values
- Mean participant age: 41.54 years ± 13.89
- Average time since T1DM diagnosis: 16.37 years ± 12.92
- Mean duration on a long-acting GLP-1: 23.85 months \pm 15.46




Reasons for discontinuation included:

- GI side effects
- Minimal or no impact on glycemic control
- Minimal or no impact on weight loss
- Lack of insurance coverage
- Unknown



RESULTS

Parameter	Mean Difference	p-value (α = 0.05)
AIc (N=43)	-0.71%	0.002
DKA (N=44)	-9 incidents	0.02
CGM TIR (N=23)	+12.15%	0.0009
CGM Highs (N=20)	-11.97%	0.006
14-Day Average BG (N=27)	-19 mg/dL	0.01
14-Day SD (N=17)	-8.45 mg/dL	0.007
Weight (N=36)	-6.97 lbs	0.007




Changes in CGM Glycemic Parameters Baseline and Post GLP-1 100 *** Baseline Post GLP-1 90 66.74 * statistically 80 significant 54.59 difference 70 ** Percentage (%) 42.20 60 30.23 50 40 30 20 3.77 2.62 10 2.32 1.78 1.56 0.70 0 Very Low (N=22) TIR (N=23) Low (N=28) High (N=20) Very High (N=19)

CONCLUSION AND DISCUSSION

- There is an urgent need for strategies to improve glycemic control and reduce morbidity and mortality in TIDM.
- Our study is the first to demonstrate significant AI c reduction and TIR increase without increased hypoglycemia and DKA risk in 54TIDM patients on long-acting GLP-I receptor agonists treated for an average of almost 2 years.
- In addition to improved glycemic control and reduced glycemic variability, there was a significant decrease in weight.
- The study represents real-world experience.
- As more data emerges on cardiovascular and renal benefits of GLP-1 receptor agonists in type 2 diabetes, this class may represent a promising adjunct therapy to insulin in individuals with type 1 diabetes





Pre/Post learning






CGM Utilization

Alisha Virani, RD, CDCES Grady Health Systems T1Dx Project Coordinator



Grady Memorial Hospital, Atlanta GA

- Safety Net Hospital
- 85% Black American
- 800-900 established adult patients with T1D



TID Exchange


Grady Diabetes Center

- 204 T1D patients
- Staffing
 - 8 physicians
 - 1 CDCES (RN), 2 CDCES (RD)
 - 2 Podiatrists, 1 Wound Care RN
 - 1 Clinical Pharmacist, CDCES
 - Social Worker, Behavioral Counselor
 - Ophthalmic technician
 - Medication Access Coordinator



TID Exchange


Data on Disparities in CGM Use



Wirunsawanya K: Racial differences in technology use among type 1 diabetes in a safety-net hospital. J Endocr Soc 2020;4(Suppl 1):OR30-03



Data on Disparities in CGM Use




Percentage of YA (aged 18-28) with T1D in each racial–ethnic group using insulin pump and CGM comparing unadjusted and fully adjusted estimates. Adjustment included: demographic and clinical variables, SES, healthcare factors, and diabetes self-management. CGM, continuous glucose monitor; T1D, type 1 diabetes; YA, young adults.

Agarwal, S, et al. Racial–Ethnic Disparities in Diabetes Technology use Among Young Adults with Type 1 Diabetes. Diabetes Technol Ther. April 2021; 23(4): 306–313. Published online 2021 Mar 22.



Data on Disparities in CGM Use Among Medicare Beneficiaries with T1D



Wherry K, et al. Wide Racial Gap for Diabetes Tech Use Among Medicare Patients. *J Clin Endocrinol Metab.* 2021



Disparities in CGM Use Among Medicare Beneficiaries with T1D

В Α Medicare Beneficiaries with T1D Insulin Pump Therapy, Medicare Beneficiaries with T1D CGM Therapy, by Race (2017-2019) by Race (2017-2019) of Insulin Pump Therap) 50% 50% Prevalence of CGM Therapy 40% 40% 30% 30% 24.9% 18.2% 15.9% 20% 20% 14.0% 14.1% 11.8% Prevalence 10% 4.3% 4.0% 4.3% 3.7% 3.2% 10.2% 4.6% 0.7% 1.1% [∟] 3.8% 0% 0% 3.9% 4.8% 2017 2018 2017 2018 2019 2019 Black — Other — White Black Other С Medicare Beneficiaries with T1D Any Diabetes D Medicare Beneficiaries with T1D Using Insulin Pump and Technology, by Race (2017-2019) CGM Therapy, by Race (2017-2019) MBC of Diabetes Technology 50% 50% 40% 40% Ω. 31.9% a 30% 30% 22.8% 20% 20% 15.2% ď 14.0% 12.1% 11.2% Prevalence 8.1% 7.2% 10% 10% 4.6% - 2.1% 2.5% ¬ 1.2% -1.7%4.0% à 0.5% 7.0% 0% 0% 2019 2017 2018 2019 2017 2018 -----White -Black -Other Black ----Other

Diabetes technology use by race (2017-2019) MEDICARE FFS BENEFICIARIES WITH T1D

Wherry K, et al. Racial Disparities in Diabetes Technology Use and Outcomes in Type 1 Diabetes in a Safety-Net Hospital. *J Clin Endocrinol Metab.* 2021



Barries to CGM Use- What the Data Shows

- Insurance eligibility criteria
- Patient-provider factors
 - Patient preference
 - Implicit bias
 - Structural racism
 - Patient's behavior and knowledge
 - Provider behavior
 - Patient–provider interactions
- Organizational and institutional factors
 - Institutional eligibility and allocation of diabetes technologies
 - Clinics structure decision-making processes

Fantasia KL, Wirunsawanya K, Lee C, Rizo I. Racial Disparities in Diabetes Technology Use and Outcomes in Type 1 Diabetes in a Safety-Net Hospital. Journal of Diabetes Science and Technology. 2021 Sep;15(5):1010-1017.

Agarwal S, Schechter C, Gonzalez J, Long JA. Racial-Ethnic Disparities in Diabetes Technology use Among Young Adults with Type 1 Diabetes. Diabetes Technol Ther. 2021 Apr;23(4):306-313. doi: 10.1089/dia.2020.0338. Epub 2020 Dec 1.



Barries to CGM Use- What the Our Clinic Shows

- Not being able to meet the criteria for coverage
 - Finger sticks 3-4 times per day for a month- Medicaid
- Out of pocket cost
- Low level of understanding on use of device
- Keep falling off (Freestyle Libre 2)
- Excessive paperwork and follow up from provider level
- Time needed from providers to educate patients on CGM



Possible Interventions To Address Disparity Gap in CGM Use

- Remove strict eligibility of insurance coverage criteria
 - Provider advocate to insurance companies
- Evaluate:
 - Clinician decision making regarding the use of diabetes technology
 - Role of communication regarding diabetes technology with patients
 - Barriers patients face after prescribing diabetes technology should be evaluated

Agarwal S, Schechter C, Gonzalez J, Long JA. Racial-Ethnic Disparities in Diabetes Technology use Among Young Adults with Type 1 Diabetes. Diabetes Technol Ther. 2021 Apr; 23(4): 306-313

Glycemic Optimization Clinic (GOC)

- Low technology use for patients in our clinic
 - <5% of patient come to us on technology</p>
 - Barriers with affordability
 - Lack of proper support for those on pumps/CGMs (ie, time, resources to obtain supplies, etc)
- Development of GOC
 - Initiated as technology clinic, but evolved into clinic for people living with T1D
 - Goals:
 - Improve glycemic control and management for existing TID clinic patients
 - Patients to prioritize
 - Those with frequent admissions, particularly recurrent DKA, hypoglycemia
 - Those currently using diabetes technology (insulin pumps, continuous glucose monitors)
 - Those with significant social obstacles impacting adherence/care
 - Multidisciplinary management is key



Diabetes Clinic vs GOC Appointment Flow

Diabetes Clinic

• Patients seen by MD for medical visit

(30-minute appointments)


- Discharged by RN to go over medication changes, medication teaching, and other relevant diabetes education
- Patients assessed for other provider referrals.
 Usually do not see other providers on same day of their visit
- Medication Access Coordinator

• GOC

- Patient already established in diabetes center
- See MD/PharmD/RD/CDCES/Social Worker/Medication Access Coordinatorinterdisciplinary approach to care
 (60 to 90-minute appointments)
- Follow up in GOC tailored to patient needs
 - Carb counting
 - Medication management
 - Insulin pump education/management
 - CGM education





CGM Use Over One Year



T1D Exchange

Population Analysis of Patients Using CGM







Next Steps/Future Interventions

- CGM utilization vs CGM RX
 - Created flowsheet
- Method of implementation to capture correct data
- Continue to streamline process with parachute and having point person that will correspond with the various DME and insurance companies
- Continue to work towards offering CGM classes to promote continued CGM utilization with patients



Insulin	Types	and	Doses
---------	-------	-----	-------

LONG ACTING INSULIN						
Glargine (Lantus/Basalgar)	70/30 N/R	NPH	Detemir (Levemir) 70/30 N/Novolog	75/25 N/Humalog	T C
Degludec (Tresiba)						
Long-acting insulin units a	it breakfast		L	ong-acting insulin	units at lunch	
	lvn					

Long-acting insulin units H.S.

....

V D

~

~

Long-acting insulin units at supper

SHORT ACTING INSUL	N			
Aspart (Novolog)	Lispro (Humalog/Admelog)	Regular (Novolin or Hum	۳ [1
Glulisine (Apidra)	U-500			
Short-acting insulin units	at breakfast	Short-acting insulin	units at lunch	
Short-acting insulin units	at supper	Short-acting insulin	units H.S.	
Blood Glucose History				
Tests/day (download)		Tests/day (self-repo	rt)	

CGM	
Yes No 🖳	
Before breakfast	\$
Glucose range before breakfast	
	٣ [
Hypoglycemia before breakfast	
Yes No Fill V	
Post-Breakfast	3
Glucose range after breakfast	
	٣ [
Hypoglycemia after breakfast	
yes no Fill V	
Before lunch	\$
Glucose range before lunch	
	V [
Hypoglycemia before lunch	
yes no 🖷 📉 🗅	



Post lunch

*

Glucose range post lunch

Hypoglycemia after lunch yes no 🖷 🔻 🗅			
Before dinner	*	Since last visit	*
Glucose range before dinner		Last DM Clinic Appt	
	۷ ۵		
Hypoglycemia before dinner		ER visits for diabetes	
yes no 📲		0 1 2 3 4 5 >5	
After dinner	*	Hospitalizations for DKA or HHS	
Glucose range after dinner	۲ 🗅	0 1 2 3 4 5 >5	
Hypoglycemia after dinner		ED Visits or Hospitalizations for Hypoglycemia	
yes no 🖼 y		0 1 2 3 4 5 >5 T	
Bedtime	*	Hypoglycemia requiring help:	*
Glucose range at bedtime		LOC	
	۳ ۵	0 1 2 3 4 5 >5	
Hypoglycemia at bedtime		Feel low when BG is <60?	
yes no 📲		Yes No Sometimes T	
		Interval History Comments	
			V D



Insulin Regimen						*
Date of Insulin Pun	np Start					
I	7					
Insulin Regimen						
Pump + POC (Op	pen Loop)	Sensor	augment Pump (Ope	n Hybrid C	losed Loop	V D
Low Glucose s	uspend	Predic	tive Low glucose Susp	oend Other	(free text)	
Brand						
Medtronic 530G	Medtronic	630G	Medtronic 770G	Omnipod Dash	Omnipod 5	
T Slim X2 Basal IQ	Other (Con	nment)	None			
Carb Counting						
Yes No 🛱 🔻						
I:C Ratio (e.g.1:10)						
						V D
Boluses per day				Average Bolus unit	ts per day	
Active Time				% of time in closed	l loop	
	7					
То			* Total	Daily Basal Insuli	n	
) V		Total	Daily Basal Insulin (u/day)	
					V D	

Basal Rate:

Rate (Unit)

From



~

TIDX-QI Publications Updates



Publications Policy



T1D Exchange Quality Improvement Collaborative (T1DX-QI) Publication Policy and Procedure

1. Objectives

This policy describes the process for T1DX-QI publications and presentations.


2. Definitions

T1DX-QI includes clinical centers participating in the collaborative that have signed data agreements with T1D Exchange and share data for quality improvement/population hearesearch.

3. Publications

A publication is any document submitted to a professional journal with regional or nation circulation. Approval of publications may be withheld until such time as deemed appropriate the Publication Committee. Prior publications and presentations can be found <u>here.</u>

- A. Projects can be proposed by completing the <u>application form</u>.
- B. Workflow process:
 - First/Soniar author submits proposal manuscript idea to Coordinating Cont



Last revised 7/11/22

Exchange

T1DX-QI HEALTH EQUITY STUDY IS ONE OF TOP TEN DISPARITIES ABSTRACT PRESENTED AT ADA 2022 SCIENTIFIC CONFERENCE



June 1, 2022

Dear Dr. Osagie Ebekozien,

On behalf of the American Diabetes Association, we would like to extend our heartfelt congratulations to you on having been selected as a recipient of the National Health Disparities Committee's Top 10 Recommended Abstracts for the following abstract:

Abstract #4224

Inequities in Glycemic Outcomes for Patients with Type 1 Diabetes: Six-Year (2016–2021) Longitudinal Follow-Up by Race and Ethnicity of 36,390 Patients in the T1Dx-QI Collaborative

OSAGIE EBEKOZIEN, NUDRAT NOOR, MANMOHAN K. KAMBOJ, ORI ODUGBESAN, SHIDEH MAJIDI, RACHEL HOPKINS, EMILY L. DEWIT, ROBERTO IZQUIERDO, SHIVANI AGARWAL, ANASTASIA ALBANESE-O'NEILL, DAVID M. MAAHS, MARK A. CLEMENTS, T1DX-QI COLLABORATIVE

The Health Disparities Committee's Top 10 Recommended Abstracts recognizes health disparities related abstracts that have been accepted to the American Diabetes Association 82nd Scientific Sessions. These abstracts focus on health care disparities/inequities in diabetes outcomes. The ideal selections may detail research that helps us understand factors underlying diabetes disparities and inequities or demonstrates practical interventions that may contribute to eliminating them. For additional information please visit: professional.diabetes.org/HDCabstracts.

Once again, congratulations on this much-deserved recognition for your significant contributions to the diabetes community.

Sincerely,

Dr. A. Enrique Caballero Harvard Medical School Chair, National Health Disparities Committee



T1DX-QI PAPER IS THE CURRENT MOST CITED ARTICLE 2020-2022 IN THE JOURNAL OF DIABETES

Articles



Increased DKA at presentation among newly diagnosed type 1 diabetes patients with or without COVID-19: Data from a multi-site surveillance registry

Kara Beliard, Osagie Ebekozien, Carla Demeterco-Berggren, Guy Todd Alonso, Mary Pat Gallagher, Mark Clements, Robert Rapaport

Journal of Diabetes | Pages: 270-272 | First Published: 7 December 2020

	Category	Positive COVID-19 test (n = 24)	Negative COVID-19 test (n = 124)	P value
Mean age at diagnosis (SD)		15.64 (15.35)	10.84 (5. 43)	.14
Age categories	0-10 y/o	7 (29)	59 (48)	.11
	11-19 y/o	15 (63)	64 (52)	.37
	>19 y/o	2 (8)	1(1)	.06
Gender	Female	13 (54)	59 (48)	.65
Race/ethnicity	NH White	3 (13)	75 (60)	<.001
	NH Black	7 (29)	0 (0)	<.001
	Hispanic	10 (42)	26 (21)	.03
	Other/unknown	4 (17)	23 (19)	1
Median HgA1C (IQR)		12.4 (2.9)	13.1 (2.7)	.55
Insurance*	Public	18 (75)	48 (39)	.001
	Private	6 (25)	71 (57)	.006
	Uninsured	0(0)	5 (4)	1
DKA on presentation	Yes	16 (67)	77 (62)	.81
	No	8 (33)	47 (38)	.81

Abbreviations: COVID-19, commavirus disease 2019; DKA, diabetic ketoacidesis; HhA3c, glycoxylated hemoglobin; IQR, interquartile range; NH, non Protection of the second state of the second s

Highlights

- Our multicenter study reports a higher proportion of diabetic ketoacidosis presentation of over 60% in newly diagnosed patients with type 1 diabetes with or without confirmed coronavirus disease 2019 (COVID-19) at diagnosis.
- This finding is suggestive of delays in seeking care during the COVID-19 pandemic.



T1DX-QI PAPER IS ONE OF TOP FIVE MOST READ ARTICLE 2020-2022 IN THE JOURNAL OF DIABETES

Articles

Most Recent Most Cited Most Read

The most read articles published in the last 2 years

Prevalence and impact of diabetes in hospitalized COVID-19 patients: A systematic review and meta-analysis

Sian A. Bradley, Maciej Banach, Negman Alvarado, Ivica Smokovski, Sonu M. M. Bhaskar

Journal of Diabetes | Pages: 144-157 | First Published: 23 December 2021

Abstract | Full text | PDF | References | Request permissions

Open Access

Time-limited diets and the gut microbiota in cardiometabolic disease

Karina Ratiner, Hagit Shapiro, Kim Goldenberg, Eran Elinav

Journal of Diabetes | Pages: 377-393 | First Published: 13 June 2022

Abstract | Full text | PDF | References | Request permissions

Free Access

New-onset diabetes in "long COVID"

Thirunavukkarasu Sathish, Mary Chandrika Anton, Tharsan Sivakumar

Journal of Diabetes | Pages: 693-694 | First Published: 23 April 2021

Full text | PDF | References | Request permissions

Free Access

Diabetic ketoacidosis drives COVID-19 related hospitalizations in children with type 1 diabetes

Guy Todd Alonso, Osagie Ebekozien, Mary Pat Gallagher, Saketh Rompicherla, Sarah K. Lyons, Abha Choudhary, Shideh Majidi, Catherina T. Pinnaro, Sadana Balachandar, Mariam Gangat, Alissa Jeanne Curda Roberts, Brynn E. Marks, Ana Creo, Janine Sanchez, Tossaporn Seeherunvong, Jose Jimenez-Vega, Neha S. Patel, Jamie R. Wood, Liana Gabriel, Kathryn M. Sumpter, Meredith Wilkes, Robert Rapaport, Anna Cymbaluk, Jenise C. Wong, Srinath Sanda, Anastasia Albanese-O'neill

Journal of Diabetes | Pages: 681-687 | First Published: 14 April 2021

Abstract | Full text | PDF | References | Request permissions



T1DX-QI PAPER WAS ONE OF THE TOP TEN PERCENT CITED ARTICLE 2020-2022 IN THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

JCEM THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dear Drs. Grenye O'Malley; Osagie Ebekozien; Marisa Desimone; Catherina T Pinnaro; Alissa Roberts; Sarit Polsky; Nudrat Noor; Grazia Aleppo; Marina Basina; Michael Tansey; Devin Steenkamp; Francesco Vendrame; Ilona Lorincz; Priyanka Mathias; Shivani Agarwal; Lauren Golden; Irl B Hirsh; Carol J. Levy,

Congratulations! Your The Journal of Clinical Endocrinology & Metabolism paper "COVID-19 Hospitalization in Adults with Type 1 Diabetes: Results from the T1D Exchange Multi-Center Surveillance Study" was one of the top 10 percent of articles published in the journal in 2020-2021, as assessed by rate of citation.

As you consider where to publish forthcoming work, I hope you will consider submitting your research to the Endocrine Society's family of journals. By publishing with us, you will ensure that your work will reach a global audience of influential researchers. We are delighted with the peer recognition, visibility, and readership impact your paper has received, and we would welcome the opportunity to work with you again in the future.

Please feel free to contact me to discuss your research - I am interested in learning how we can collaborate on your upcoming projects. I look forward to hearing from you, and once again, congratulations!

Tim Beardyle



T1DX-QI PAPER WAS ONE OF THE TOP TEN PERCENT CITED ARTICLE 2020-2022 IN THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

JCEM THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dear Drs. Osagie Ebekozien; Shivani Agarwal; Nudrat Noor; Anastasia Albanese O Neil; Jenise C. Wong; Tossaporn Seeherunvong; Janine Sanchez; Daniel DeSalvo; Sarah K. Lyons; Shideh Majidi; Jamie R. Wood; Runa Acharya; Grazia Aleppo; Kathryn M. Sumpter; Anna Cymbaluk; Nirali A. Shah; Michelle Van Name; Lisa Cruz-Aviles; Guy Todd Alonso; Mary Pat Gallagher; Srinath Sanda; Alexis Jamie Feuer; Kristina Cossen; Nicole Rioles; Nana-Hawa Yayah Jones; Manmohan K. Kamboj; Irl B Hirsch,

Congratulations! Your The Journal of Clinical Endocrinology & Metabolism paper "Inequities in Diabetic Ketoacidosis among Patients with Type 1 diabetes and COVID-19: Data from 52 US Clinical Centers" was one of the top 10 percent of articles published in the journal in 2020-2021, as assessed by rate of citation.

As you consider where to publish forthcoming work, I hope you will consider submitting your research to the Endocrine Society's family of journals. By publishing with us, you will ensure that your work will reach a global audience of influential researchers. We are delighted with the peer recognition, visibility, and readership impact your paper has received, and we would welcome the opportunity to work with you again in the future.

Please feel free to contact me to discuss your research - I am interested in learning how we can collaborate on your upcoming projects. I look forward to hearing from you, and once again, congratulations!

I'm Beardyle



QI Portal Updates



QI Portal – April – July 2022 updates


Expanded Health Equity features!



QI Portal – April – July 2022 updates

New notification bell!

- Notifications for new:
 - QI Portal features
 - Clinic data
 - Library article
- Change notification type in Settings




QI Portal – April – July 2022 updates

New metrics! Time in Range and Social **Determinants of Health**

New library comments!

CGM US8



Ann Mungmode Jul 25, 2022

AM

@ElizabethMann @ElizabethMann @ElizabethMann You may be interested in this

article as you explore future CGM projects!

Post

Delete

Reply

Edit

Seize the Data! Contest – September 2022

Explore the QI Portal and win a prize!

From 9-1 through 9/30, TIDX-QI will host a Seize the Data! Contest!

Weekly awards will be given for:

- Highest # of logins
- Each login = one chance to win
- Bonus chances to win if access all four QI Portal tabs

